Paper8375017
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
Denny WA and 1 other. Cancer Metastasis Rev, 1993. Cited by 70 papers, by iCite.
Cite this record
ConductScience Library. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Papers, record 8375017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8375017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytotoxins | Major topic |
| Neoplasms | Major topic |
| Nitrogen Mustard Compounds | Major topic |
| Prodrugs | Major topic |
| Animals | |
| Cell Cycle | |
| Cell Hypoxia | |
| Diffusion | |
| Drug Design | |
| Humans | |
| Molecular Structure | |
| Oxidation-Reduction |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CM 07321 | NCI NIH HHS | United States | PubMed |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3280413 | Reoxygenation and repopulation in irradiated tumors. | Front Radiat Ther Oncol | 1988 | https://conductscience.org/library/papers/3280413 | PubMed |
| 2 | 7236492 | A marker for hypoxic cells in tumours with potential clinical applicability. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7236492 | PubMed |
| 3 | 1586589 | Use of a high frequency ultrasound microscope to image the action of 2-nitroimidazoles in multicellular spheroids. | Br J Cancer | 1992 | https://conductscience.org/library/papers/1586589 | PubMed |
| 4 | 2244016 | The effects of single dose oral hydralazine on blood flow through human lung tumours. | Radiother Oncol | 1990 | https://conductscience.org/library/papers/2244016 | PubMed |
| 5 | 356975 | Cell kinetics and chemotherapy: a critical review. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/356975 | PubMed |
| 6 | 2587812 | Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069. | Radiother Oncol | 1989 | https://conductscience.org/library/papers/2587812 | PubMed |
| 7 | 1913664 | Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. | Cancer Res | 1991 | https://conductscience.org/library/papers/1913664 | PubMed |
| 8 | 679180 | Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. | Cancer Res | 1978 | https://conductscience.org/library/papers/679180 | PubMed |
| 9 | 1617656 | Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution. | Cancer Res | 1992 | https://conductscience.org/library/papers/1617656 | PubMed |
| 10 | 1562278 | The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink. | Biochem Pharmacol | 1992 | https://conductscience.org/library/papers/1562278 | PubMed |
| 11 | 2083666 | Antibody-directed enzyme/prodrug therapy (ADEPT). | Biochem Soc Trans | 1990 | https://conductscience.org/library/papers/2083666 | PubMed |
| 12 | 3360652 | Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. | Int J Radiat Oncol Biol Phys | 1988 | https://conductscience.org/library/papers/3360652 | PubMed |
| 13 | 1671692 | Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. | Int J Radiat Biol | 1991 | https://conductscience.org/library/papers/1671692 | PubMed |
| 14 | 2545340 | Acid pH in tumors and its potential for therapeutic exploitation. | Cancer Res | 1989 | https://conductscience.org/library/papers/2545340 | PubMed |
| 15 | 1727119 | Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. | Int J Radiat Oncol Biol Phys | 1992 | https://conductscience.org/library/papers/1727119 | PubMed |
| 16 | 1930294 | Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. | Biochem Pharmacol | 1991 | https://conductscience.org/library/papers/1930294 | PubMed |
| 17 | 3175048 | Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. | Radiother Oncol | 1988 | https://conductscience.org/library/papers/3175048 | PubMed |
| 18 | 482607 | Radiation survival of cells from spheroids grown in different oxygen concentrations. | Radiat Res | 1979 | https://conductscience.org/library/papers/482607 | PubMed |
| 19 | 7313077 | Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). | Radiat Res | 1981 | https://conductscience.org/library/papers/7313077 | PubMed |
| 20 | 3202902 | A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. | Biochem Pharmacol | 1988 | https://conductscience.org/library/papers/3202902 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34835785 | The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. | Nanomaterials (Basel) | 2021 | https://conductscience.org/library/papers/34835785 | PubMed |
| 33915222 | Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects. | J Control Release | 2021 | https://conductscience.org/library/papers/33915222 | PubMed |
| 33897898 | Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. | Theranostics | 2021 | https://conductscience.org/library/papers/33897898 | PubMed |
| 31190820 | Hypoxia-active nanoparticles used in tumor theranostic. | Int J Nanomedicine | 2019 | https://conductscience.org/library/papers/31190820 | PubMed |
| 30672949 | Physical properties, ligand substitution reactions, and biological activity of Co(iii)-Schiff base complexes. | Dalton Trans | 2019 | https://conductscience.org/library/papers/30672949 | PubMed |
| 30575832 | Hypoxia-targeted drug delivery. | Chem Soc Rev | 2019 | https://conductscience.org/library/papers/30575832 | PubMed |
| 30111719 | Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs. | Molecules | 2018 | https://conductscience.org/library/papers/30111719 | PubMed |
| 24409417 | Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling. | Front Oncol | 2013 | https://conductscience.org/library/papers/24409417 | PubMed |
| 24109591 | The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. | Front Oncol | 2013 | https://conductscience.org/library/papers/24109591 | PubMed |
| 22289471 | Redox activation of metal-based prodrugs as a strategy for drug delivery. | Adv Drug Deliv Rev | 2012 | https://conductscience.org/library/papers/22289471 | PubMed |
| 19924084 | Bystander or no bystander for gene directed enzyme prodrug therapy. | Molecules | 2009 | https://conductscience.org/library/papers/19924084 | PubMed |
| 12386828 | Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. | Cancer Gene Ther | 2002 | https://conductscience.org/library/papers/12386828 | PubMed |
| 10815768 | Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study. | J Comput Aided Mol Des | 2000 | https://conductscience.org/library/papers/10815768 | PubMed |
| 8763845 | Pulse radiolysis studies on the hypoxia-selective toxicity of a colbalt-mustard complex. | Br J Cancer Suppl | 1996 | https://conductscience.org/library/papers/8763845 | PubMed |
| 8763842 | Recent developments in the design of bioreductive drugs. | Br J Cancer Suppl | 1996 | https://conductscience.org/library/papers/8763842 | PubMed |
| 8611431 | Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8611431 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8375017
GET https://conductscience.org/api/papers/v1/8375017/references?page=2